除了各種臨床上常用到的經(jīng)典的腫瘤相關(guān)預(yù)后因子外,，國(guó)內(nèi)外研究人員一直認(rèn)為：腫瘤患者的個(gè)體體征也可能會(huì)影響乳腺癌的發(fā)展。
為了研究激素受體陽(yáng)性的患有乳腺癌絕經(jīng)的女性患者,，年齡與乳腺癌病情發(fā)展結(jié)果兩者之間的聯(lián)系,，Willemien van de Water博士等科學(xué)家對(duì)他莫西芬依西美坦佐劑在不同民族間的隨機(jī)臨床實(shí)驗(yàn)（TEAM）所納入的9766例患者進(jìn)行了相關(guān)分析研究。相關(guān)研究論文發(fā)表在2月8日J(rèn)AMA雜志上,。
2001年1月份,，TEAM實(shí)驗(yàn)正式開(kāi)始進(jìn)行，實(shí)驗(yàn)研究一直持續(xù)到2006年1月份才結(jié)束,。雜在這項(xiàng)研究中,，研究人員根據(jù)就診時(shí)乳腺癌患者的年齡，將這些受試者分為3組,，分別是年齡小于65歲組(樣本量n=5349),，年齡介于65至74歲組(n=3060)，年齡大于75歲組(n=1357),。
工作者首先統(tǒng)計(jì)了乳腺癌患者死亡率結(jié)果,，其次還統(tǒng)計(jì)了引發(fā)乳腺癌患者死亡的原因以及患者乳腺癌復(fù)發(fā)的概率,。
結(jié)果表明：在平均為5.1年的隨訪時(shí)期內(nèi),，約有1043名乳腺癌患者出現(xiàn)死亡,。各組乳腺癌患者組的死亡率與組內(nèi)總死亡率的比值隨著年齡的降低而呈現(xiàn)遞減的趨勢(shì)，65歲以下組死亡率為78%,，介于65至74歲組死亡率為56%,，年齡大于75歲組死亡率是36%,。
然而，在多變量分析結(jié)果中上述趨勢(shì)出現(xiàn)了變化：與65歲以下組相比,，乳腺癌患者死亡率隨著年齡的增大而呈現(xiàn)上升趨勢(shì),。由此，研究人員下結(jié)論稱：對(duì)于激素受體陽(yáng)性的患有乳腺癌絕經(jīng)的女性患者而言,，年齡越大,，其死于乳腺癌的可能性就越大。(生物谷 Bioon.com)
doi:10.1001/jama.2012.84
PMC:
PMID:
Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer
Willemien van de Water, MD;Christos Markopoulos, MD, PhD;Cornelis J. H. van de Velde, MD, PhD; et al.
Context In addition to classic tumor-related prognostic factors, patient characteristics may be associated with breast cancer outcome.
Objective To assess the association between age at diagnosis and breast cancer outcome in postmenopausal women with hormone receptor–positive breast cancer.
Design, Setting, and Patients Study analysis of 9766 patients enrolled in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) randomized clinical trial between January 2001 and January 2006. Age at diagnosis was categorized as younger than 65 years (n=5349), 65 to 74 years (n=3060), and 75 years or older (n=1357).
Main Outcome Measures Primary end point was disease-specific mortality; secondary end points were other-cause mortality and breast cancer relapse.
Results During median follow-up of approximately 5.1 years, there were a total of 1043 deaths. Disease-specific mortality, as a proportion of all-cause mortality, decreased with categorical age group (78% [<65 years], 56% [65-74 years], and 36% [≥75 years]; P < .001). In multivariable analyses, compared with patients younger than 65 years, disease-specific mortality increased with age for patients aged 65 to 74 years (hazard ratio [HR], 1.25; 95% CI, 1.01-1.54); and patients aged 75 years or older (HR, 1.63; 95% CI, 1.23-2.16) (P < .001). Similarly, breast cancer relapse increased with age for patients aged 65-74 years (HR, 1.07; 95% CI, 0.91-1.25 and patients aged 75 years or older (HR, 1.29; 95% CI, 1.05-1.60) (P = .06). Other-cause mortality increased with age in patients aged 65 to 74 years (HR, 2.66; 95% CI, 1.96-3.63) and patients aged 75 years or older (HR, 7.30; 95% CI, 5.29-10.07) (P < .001).
Conclusion Among postmenopausal women with hormone receptor–positive breast cancer, increasing age was associated with a higher disease-specific mortality.
